Switch theme
Sign up to access all valuation multiples
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
1897
6.1K+
LTM Revenue $2.7B
LTM EBITDA $479M
$4.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sumitomo Pharma has a last 12-month revenue (LTM) of $2.7B and a last 12-month EBITDA of $479M.
In the most recent fiscal year, Sumitomo Pharma achieved revenue of $2.8B and an EBITDA of $392M.
Sumitomo Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sumitomo Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.7B | XXX | $2.8B | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $1.7B | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 62% | XXX | XXX | XXX |
| EBITDA | $479M | XXX | $392M | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 14% | XXX | XXX | XXX |
| EBIT | $339M | XXX | $206M | XXX | XXX | XXX |
| EBIT Margin | 13% | XXX | 7% | XXX | XXX | XXX |
| Net Profit | $213M | XXX | $164M | XXX | XXX | XXX |
| Net Margin | 8% | XXX | 6% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $2.0B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 16, 2025, Sumitomo Pharma's stock price is JPY 1016 (or $7).
Sumitomo Pharma has current market cap of JPY 404B (or $2.8B), and EV of JPY 669B (or $4.6B).
See Sumitomo Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.6B | $2.8B | XXX | XXX | XXX | XXX | $0.54 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 16, 2025, Sumitomo Pharma has market cap of $2.8B and EV of $4.6B.
Sumitomo Pharma's trades at 1.8x EV/Revenue multiple, and -24.1x EV/EBITDA.
Equity research analysts estimate Sumitomo Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sumitomo Pharma has a P/E ratio of 13.1x.
See valuation multiples for Sumitomo Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.8B | XXX | $2.8B | XXX | XXX | XXX |
| EV (current) | $4.6B | XXX | $4.6B | XXX | XXX | XXX |
| EV/Revenue | 1.7x | XXX | 1.8x | XXX | XXX | XXX |
| EV/EBITDA | 9.7x | XXX | -24.1x | XXX | XXX | XXX |
| EV/EBIT | 13.7x | XXX | -10.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | 13.1x | XXX | -6.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -10.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSumitomo Pharma's last 12 month revenue growth is -5%
Sumitomo Pharma's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Sumitomo Pharma's rule of 40 is -13% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sumitomo Pharma's rule of X is 5% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Sumitomo Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -5% | XXX | 0% | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | -7% | XXX | XXX | XXX |
| EBITDA Growth | 12% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -13% | XXX | -13% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 5% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 13% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 54% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sumitomo Pharma acquired XXX companies to date.
Last acquisition by Sumitomo Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Sumitomo Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Sumitomo Pharma founded? | Sumitomo Pharma was founded in 1897. |
| Where is Sumitomo Pharma headquartered? | Sumitomo Pharma is headquartered in Japan. |
| How many employees does Sumitomo Pharma have? | As of today, Sumitomo Pharma has 6.1K+ employees. |
| Is Sumitomo Pharma publicy listed? | Yes, Sumitomo Pharma is a public company listed on TKS. |
| What is the stock symbol of Sumitomo Pharma? | Sumitomo Pharma trades under 4506 ticker. |
| When did Sumitomo Pharma go public? | Sumitomo Pharma went public in 1949. |
| Who are competitors of Sumitomo Pharma? | Similar companies to Sumitomo Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Sumitomo Pharma? | Sumitomo Pharma's current market cap is $2.8B |
| What is the current revenue of Sumitomo Pharma? | Sumitomo Pharma's last 12 months revenue is $2.7B. |
| What is the current revenue growth of Sumitomo Pharma? | Sumitomo Pharma revenue growth (NTM/LTM) is -5%. |
| What is the current EV/Revenue multiple of Sumitomo Pharma? | Current revenue multiple of Sumitomo Pharma is 1.7x. |
| Is Sumitomo Pharma profitable? | Yes, Sumitomo Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sumitomo Pharma? | Sumitomo Pharma's last 12 months EBITDA is $479M. |
| What is Sumitomo Pharma's EBITDA margin? | Sumitomo Pharma's last 12 months EBITDA margin is 18%. |
| What is the current EV/EBITDA multiple of Sumitomo Pharma? | Current EBITDA multiple of Sumitomo Pharma is 9.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
